Financial Contrast: Rigel Pharmaceuticals (RIGL) and Ocata Therapeutics (OCAT)
Rigel Pharmaceuticals (NASDAQ: RIGL) and Ocata Therapeutics (NASDAQ:OCAT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitabiliy, risk, valuation, institutional ownership, dividends and earnings.
This table compares Rigel Pharmaceuticals and Ocata Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and target prices for Rigel Pharmaceuticals and Ocata Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Rigel Pharmaceuticals presently has a consensus target price of $6.40, indicating a potential upside of 145.21%. Given Rigel Pharmaceuticals’ higher probable upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than Ocata Therapeutics.
Institutional & Insider Ownership
89.9% of Rigel Pharmaceuticals shares are owned by institutional investors. 5.2% of Rigel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Rigel Pharmaceuticals and Ocata Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Rigel Pharmaceuticals||$18.94 million||16.87||-$61.86 million||($0.68)||-3.84|
Ocata Therapeutics has higher revenue, but lower earnings than Rigel Pharmaceuticals.
Rigel Pharmaceuticals beats Ocata Therapeutics on 7 of the 8 factors compared between the two stocks.
Rigel Pharmaceuticals Company Profile
Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms. The Company’s clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The Company has submitted a new drug application (NDA) to the United States food and drug administration (FDA) for fostamatinib in patients with chronic or persistent immune thrombocytopenia (ITP). In addition, the Company has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics. The Company is engaged in conducting research in the disease areas of inflammation/immunology and muscle wasting/muscle endurance.
Ocata Therapeutics Company Profile
Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company’s advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.
Receive News & Ratings for Rigel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.